Brief: Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results
13/04/2023 21:05
April 13 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS REPORTS FIRST QUARTER FISCAL 2023
FINANCIAL
RESULTS AND PROVIDES A CORPORATE UPDATE
* MAINTAINED STRONG FINANCIAL POSITION WITH CASH AND
MARKETABLE
SECURITIES OF $325.6 MILLION AS OF FEBRUARY 28, 2023
* QTRLY LOSS PER SHARE $0.75
* Q1 EARNINGS PER SHARE VIEW $-0.87 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX57DMVc
Further company coverage: NRIX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis